MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes

被引:30
作者
Nakahara, Hiroshi [1 ]
Yasuda, Yukiko [1 ]
Machida, Eiichiro [1 ]
Maeda, Yorio [1 ]
Furusawa, Hidemi [1 ]
Komaki, Kansei [1 ]
Funagayama, Mayumi [1 ]
Nakahara, Mayumi [2 ]
Tamura, Shozo [2 ]
Akiyama, Futoshi [3 ]
机构
[1] Breastopia Med Corp, Breastopia Namba Hosp, Miyazaki 8800052, Japan
[2] Miyazaki Univ, Miyazaki Med Coll, Dept Radiol, Miyazaki 8891692, Japan
[3] Canc Inst Hosp, Dept Pathol, Tokyo 1358550, Japan
关键词
Triple negative breast cancer; Neoadjuvant chemotherapy; Magnetic resonance imaging; Ultrasonography; Pathology; PREOPERATIVE CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; RESIDUAL DISEASE; THERAPY; ACCURACY; TUMORS; FEASIBILITY; MAMMOGRAPHY; SONOGRAPHY; CARCINOMA;
D O I
10.1007/s12282-010-0235-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neoadjuvant chemotherapy (NAC) is commonly utilized to treat operable breast cancer. The purpose of this study was to review the findings of ultrasonography (US) and magnetic resonance (MR) imaging in patients treated with breast conservation surgery (BCS) after NAC with a focus on intrinsic subtypes. Eighty-six patients underwent BCS after NAC. The tumors were classified into four subgroups by receptor status. US and MR were performed before and after NAC. The tumor diameters in US and MR after NAC were examined for correlations with pathological tumor distances in the specimens from BCS after NAC. The correlation coefficient (r) of US to pathological tumor size was 0.3 in all tumors, 0.6 in HER2-type tumors, and 0.7 in triple negative breast cancers (TNBC). The correlation coefficient of tumor size in MR to pathological tumor size was 0.9 in TNBC, and other correlations were not statistically significant. The correlation between tumor size in MR and pathological tumor size in triple negative breast cancers corresponded best. This information is one of the clues to selecting patients for BCS after NAC.
引用
收藏
页码:152 / 160
页数:9
相关论文
共 36 条
[11]   Breast conservation after neoadjuvant chemotherapy - A prognostic index for clinical decision-making [J].
Chen, AM ;
Meric-Bernstam, F ;
Hunt, KK ;
Thames, HD ;
Outlaw, ED ;
Strom, EA ;
McNeese, MD ;
Kuerer, HM ;
Ross, MI ;
Singletary, SE ;
Ames, FC ;
Feig, BW ;
Sahin, AA ;
Perkins, GH ;
Babiera, G ;
Hortobagyi, GN ;
Buchholz, TA .
CANCER, 2005, 103 (04) :689-695
[12]   MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy [J].
Chen, Jeon Hor ;
Feig, Lyon ;
Agrawal, Garima ;
Yu, Hon ;
Carpenter, Philip M. ;
Mehta, Rita S. ;
Nalcioglu, Orhan ;
Su, Min Ying .
CANCER, 2008, 112 (01) :17-26
[13]   Impact of MRI-Evaluated Neoadjuvant Chemotherapy Response on Change of Surgical Recommendation in Breast Cancer [J].
Chen, Jeon-Hor ;
Feig, Byron A. ;
Hsiang, David J-B ;
Butler, John A. ;
Mehta, Rita S. ;
Bahri, Shadfar ;
Nalcioglu, Orhan ;
Su, Min-Ying .
ANNALS OF SURGERY, 2009, 249 (03) :448-454
[14]   Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].
Fisher, B ;
Bryant, J ;
Wolmark, N ;
Mamounas, E ;
Brown, A ;
Fisher, ER ;
Wickerham, DL ;
Begovic, M ;
DeCillis, A ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV ;
Bear, HD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685
[15]   Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients [J].
Garimella, V. ;
Qutob, O. ;
Fox, J. N. ;
Long, E. D. ;
Chaturvedi, A. ;
Turnbull, L. W. ;
Drew, P. J. .
EJSO, 2007, 33 (02) :157-161
[16]   LOCAL ADVANCED BREAST-CANCER - CONTRAST-ENHANCED SUBTRACTION MR-IMAGING OF RESPONSE TO PREOPERATIVE CHEMOTHERAPY [J].
GILLES, R ;
GUINEBRETIERE, JM ;
TOUSSAINT, C ;
SPIELMAN, M ;
RIETJENS, M ;
PETIT, JY ;
CONTESSO, G ;
MASSELOT, J ;
VANEL, D .
RADIOLOGY, 1994, 191 (03) :633-638
[17]   Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease [J].
Gralow, Julie R. ;
Burstein, Harold J. ;
Wood, William ;
Hortobagyi, Gabriel N. ;
Gianni, Luca ;
Von Minckwitz, Gunter ;
Buzdar, Aman U. ;
Smith, Ian E. ;
Symmans, William F. ;
Singh, Baljit ;
Winer, Eric P. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) :814-819
[18]  
HORTOBAGYI GN, 1988, CANCER-AM CANCER SOC, V62, P2507, DOI 10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO
[19]  
2-D
[20]   Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy [J].
Jeruss, Jacqueline S. ;
Mittendorf, Elizabeth A. ;
Tucker, Susan L. ;
Gonzalez-Angulo, Ana M. ;
Buchholz, Thomas A. ;
Sahin, Aysegul A. ;
Cormier, Janice N. ;
Buzdar, Aman U. ;
Hortobagyi, Gabriel N. ;
Hunt, Kelly K. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :246-252